Document Detail


Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy.
MedLine Citation:
PMID:  22076833     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report for the first time the impact of neoadjuvant oral low-dose chemotherapy consisting of oral trofosfamide, idarubicin, and etoposide (O-TIE) in the case of alveolar rhabdomyosarcoma (RMS) in the lower jaw of an 18-year-old woman at 27 weeks of gestation, without fetal complications and a highly efficient anti-tumor response. Our study suggests the possible application of O-TIE treatment in a neoadjuvant setting during pregnancy and recommends a schedule that can be considered for the treatment of patients with high-risk sarcomas who cannot be treated with intensive chemotherapy for various reasons.
Authors:
Meinolf Siepermann; Ewa Koscielniak; Tobias Dantonello; Dirk Klee; Joachim Boos; Barbara Krefeld; Arndt Borkhardt; Thomas Hoehn; Alexzander Asea; Rüdiger Wessalowski
Related Documents :
9248933 - Are adolescents accurate in self-report of frequencies of sexually transmitted diseases...
16884053 - Time-to-collision judgments under realistic driving conditions.
23182803 - Adverse pregnancy outcomes in cases involving extremely young maternal age.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-01-16
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  58     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-11-14     Completed Date:  2012-01-12     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  104-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Wiley Periodicals, Inc.
Affiliation:
Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / administration & dosage,  analogs & derivatives
Dose-Response Relationship, Drug
Etoposide / administration & dosage
Female
Humans
Idarubicin / administration & dosage
Pregnancy
Pregnancy Complications, Neoplastic / drug therapy*
Prognosis
Rhabdomyosarcoma, Alveolar / drug therapy*
Grant Support
ID/Acronym/Agency:
R01CA91889/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
33419-42-0/Etoposide; 50-18-0/Cyclophosphamide; 58957-92-9/Idarubicin; H64JRU6GJ0/trofosfamide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed h...
Next Document:  Health Consequences of Obesity.